Literature DB >> 12952915

Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development.

Ralf C Zimmermann1, Tipton Hartman, Suzanne Kavic, Samuel A Pauli, Peter Bohlen, Mark V Sauer, Jan Kitajewski.   

Abstract

Gonadotropins induce ovarian follicle growth that is coincident with increased follicular vasculature, suggesting a role of angiogenesis in follicle development. Functional studies performed in nonhuman primates show that administration of substances that inactivate VEGF block the development and function of preovulatory follicles as demonstrated by histological analysis or hormone measurements. Blockage of function of VEGF receptor 2 (VEGFR-2) alters follicular hormone secretion, suggesting that the intraovarian effect of VEGF might be mediated by this receptor. The specific mechanism by which follicular development was blocked in these previous studies remains unclear, however. Here we characterize the intraovarian role of VEGFR-2 activity on follicular development by choosing a model in which active feedback is absent, the prepuberally hypophysectomized mouse. Hypophysectomy prevents advanced follicle growth and maturation; however, follicle development to the preovulatory stage can be stimulated by administration of gonadotropins. We report that exogenously administered gonadotropins are unable to drive follicle development to the preovulatory stage in the presence of antiangiogenic agent, VEGFR-2-neutralizing Ab's. This inhibition of follicular development is caused by arrests to both angiogenesis and antrum formation. We conclude that the intraovarian VEGF/VEGFR-2 pathway is critical for gonadotropin-dependent angiogenesis and follicular development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952915      PMCID: PMC182212          DOI: 10.1172/JCI18740

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

Review 1.  Angiogenesis in ovarian follicular and luteal development.

Authors:  T M Hazzard; R L Stouffer
Journal:  Baillieres Best Pract Res Clin Obstet Gynaecol       Date:  2000-12

2.  Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey.

Authors:  R C Zimmermann; E Xiao; N Husami; M V Sauer; R Lobo; J Kitajewski; M Ferin
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

3.  Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (vascular endothelial growth factor Trap(A40)).

Authors:  C Wulff; S J Wiegand; P T Saunders; G A Scobie; H M Fraser
Journal:  Endocrinology       Date:  2001-07       Impact factor: 4.736

4.  Identification of an angiogenic mitogen selective for endocrine gland endothelium.

Authors:  J LeCouter; J Kowalski; J Foster; P Hass; Z Zhang; L Dillard-Telm; G Frantz; L Rangell; L DeGuzman; G A Keller; F Peale; A Gurney; K J Hillan; N Ferrara
Journal:  Nature       Date:  2001-08-30       Impact factor: 49.962

Review 5.  Initial and cyclic recruitment of ovarian follicles.

Authors:  E A McGee; A J Hsueh
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

6.  Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea.

Authors:  R C Zimmermann; T Hartman; P Bohlen; M V Sauer; J Kitajewski
Journal:  Microvasc Res       Date:  2001-07       Impact factor: 3.514

Review 7.  Role of angiopoietins in reproductive tract angiogenesis.

Authors:  E Geva; R B Jaffe
Journal:  Obstet Gynecol Surv       Date:  2000-08       Impact factor: 2.347

8.  Water permeability of an ovarian antral follicle is predominantly transcellular and mediated by aquaporins.

Authors:  Nisha A McConnell; Raheela S Yunus; Stephen A Gross; Kenneth L Bost; Mark G Clemens; Francis M Hughes
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

9.  Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2.

Authors:  Christine Wulff; Helen Wilson; Stanley J Wiegand; John S Rudge; Hamish M Fraser
Journal:  Endocrinology       Date:  2002-07       Impact factor: 4.736

10.  Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey.

Authors:  Ralf C Zimmermann; Ennian Xiao; Peter Bohlen; Michel Ferin
Journal:  Endocrinology       Date:  2002-07       Impact factor: 4.736

View more
  28 in total

1.  Dynamic phosphorylation of VE-cadherin Y685 throughout mouse estrous cycle in ovary and uterus.

Authors:  Adama Sidibé; Helena Polena; Jeremy Razanajatovo; Tiphaine Mannic; Nicolas Chaumontel; Soumalamaya Bama; Irène Maréchal; Philippe Huber; Danielle Gulino-Debrac; Laurence Bouillet; Isabelle Vilgrain
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-23       Impact factor: 4.733

2.  Synergy of Paracrine Signaling During Early-Stage Mouse Ovarian Follicle Development In Vitro.

Authors:  Hong Zhou; Joseph T Decker; Melissa M Lemke; Claire E Tomaszweski; Lonnie D Shea; Kelly B Arnold; Ariella Shikanov
Journal:  Cell Mol Bioeng       Date:  2018-08-09       Impact factor: 2.321

3.  Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues.

Authors:  Nathalie Lambeng; Yann Wallez; Christine Rampon; Francine Cand; Georges Christé; Danielle Gulino-Debrac; Isabelle Vilgrain; Philippe Huber
Journal:  Circ Res       Date:  2005-01-20       Impact factor: 17.367

4.  Ovarian function following targeted anti-angiogenic therapy with bevacizumab.

Authors:  Atsushi Imai; Satoshi Ichigo; Kazutoshi Matsunami; Hiroshi Takagi; Ichiro Kawabata
Journal:  Mol Clin Oncol       Date:  2017-05-05

5.  Vascular endothelial growth factor receptor 2 (VEGFR-2) functions to promote uterine decidual angiogenesis during early pregnancy in the mouse.

Authors:  Nataki C Douglas; Hongyan Tang; Raul Gomez; Bronislaw Pytowski; Daniel J Hicklin; Christopher M Sauer; Jan Kitajewski; Mark V Sauer; Ralf C Zimmermann
Journal:  Endocrinology       Date:  2009-04-30       Impact factor: 4.736

6.  Role of the phosphatidylinositol-3-kinase and extracellular regulated kinase pathways in the induction of hypoxia-inducible factor (HIF)-1 activity and the HIF-1 target vascular endothelial growth factor in ovarian granulosa cells in response to follicle-stimulating hormone.

Authors:  Hena Alam; Jennifer Weck; Evelyn Maizels; Youngkyu Park; Eun Jig Lee; Margaret Ashcroft; Mary Hunzicker-Dunn
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

7.  Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro.

Authors:  Divya K Shah; K M J Menon; Lourdes M Cabrera; Anjel Vahratian; Shahryar K Kavoussi; Dan I Lebovic
Journal:  Fertil Steril       Date:  2009-04-01       Impact factor: 7.329

8.  VEGFR-3 neutralization inhibits ovarian lymphangiogenesis, follicle maturation, and murine pregnancy.

Authors:  Joseph M Rutkowski; Jong Eun Ihm; Seung Tae Lee; Witold W Kilarski; Veronique I Greenwood; Miriella C Pasquier; Alexandra Quazzola; Didier Trono; Jeffrey A Hubbell; Melody A Swartz
Journal:  Am J Pathol       Date:  2013-09-13       Impact factor: 4.307

Review 9.  VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status.

Authors:  Nikita Naredi; Pankaj Talwar; K Sandeep
Journal:  Med J Armed Forces India       Date:  2012-09-11

10.  Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation.

Authors:  Hena Alam; Evelyn T Maizels; Youngkyu Park; Shail Ghaey; Zachary J Feiger; Navdeep S Chandel; Mary Hunzicker-Dunn
Journal:  J Biol Chem       Date:  2004-02-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.